Biotech Archives - Page 37 of 795

2 minute read

Fusion Pharmaceuticals Announces First Patient Dosed In The Phase 2 Portion Of The AlphaBreak Trial Evaluating FPI-2265 In Metastatic Castration-Resistant Prostate Cancer

May 9, 5:28 PM

AlphaBreak is a Phase 2/3 registrational program for FPI-2265 in patients with metastatic castration-resistant prostate cancerHAMILTON, ON and BOSTON, May 9, 2024 /CNW/ -- Fusion Pharmaceuticals Inc. (NASDAQ:FUSN),

FUSN

2 minute read

Anaptys Top-Line GEMINI-2 Phase 3 Clinical Trial Results Of Imsidolimab In Generalized Pustular Psoriasis; Patients Who Received A Single Dose Of 750mg IV Imsidolimab, 53% Achieved A GPP Physician Global Assessment Score Of 0/1 (Clear Or Almost Clear S…

By Benzinga Newsdesk

May 9, 5:06 PM

All eight patients from GEMINI-1 who responded to a single intravenous (IV) imsidolimab dose and were subsequently re-randomized to monthly subcutaneous (SC) maintenance dosing of imsidolimab in GEMINI-2 through at least

ANAB

2 minute read

Analysts’ Varied Perspectives On CytomX’s CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer

By Vandana Singh

May 9, 2:59 PM

Initial data from CytomX Therapeutics' CX-904 Phase 1a study shows safety and anti-cancer activity in heavily pretreated patients with advanced metastatic solid tumors. Reductions observed, especially in pancreatic cancer, with stable disease maintained.

CTMX

2 minute read

Weak Sales From Lipitor, Norvasc Hurt Viatris’ Q1 Earnings, Lowers Annual Forecast

By Vandana Singh

May 9, 2:23 PM

Viatris reports Q1 EPS in line with consensus at $0.67, with sales slightly missing expectations at $3.66 billion. Strong growth in Emerging Markets and Europe offset by challenges in North America. Guidance adjusted slightly downward for 2024.

VTRS

1 minute read

What’s Going On With Dermatitis-Focused RAPT Therapeutics Stock On Thursday?

By Vandana Singh

May 9, 2:12 PM

RAPT Therapeutics closes Phase 2 trials for zelnecirnon in atopic dermatitis & asthma following FDA clinical hold due to liver failure.

RAPT

2 minute read

Japan’s Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%

By Vandana Singh

May 9, 1:46 PM

Takeda Pharmaceutical (NYSE: TAK) reveals fiscal year 2023 results & restructuring plan. Revenue up 5.9%, net profit down 54.6%. Expecting operating profit of 225 billion yen in 2024.

TAK

1 minute read

Jaguar Health Announces Submission Of Clinical Trial Applications For Crofelemer To Treat Rare Disease Indications Microvillus Inclusion Disease And Short Bowel Syndrome In Europe

By Benzinga Newsdesk

May 9, 10:40 AM

Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBSSAN FRANCISCO, CA / ACCESSWIRE / May 9, 2024 / Jaguar

JAGX

1 minute read

Capricor Therapeutics To Present Exosome Platform Updates At ASGCT 27th Annual Meeting; Preclinical Findings Show Exosome-Based Therapeutic Approach For The Treatment Of Arginase-1 Deficiency

By Benzinga Newsdesk

May 9, 9:39 AM

-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024-SAN DIEGO, May 09, 2024

CAPR

1 minute read

Poseida Highlights Progress On Its Genetic Medicine Programs At The American Society For Gene And Cell Therapy 27th Annual Meeting

By Benzinga Newsdesk

May 9, 9:35 AM

Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profilePreclinical P-FVIII-101 data highlight

PSTX

2 minute read

Surrozen Presents Data Demonstrating The Promise Of Antibody-Based Wnt Mimetics In Treating Cornea Endothelial Dystrophies And Dry Eye Disease At The ARVO Annual Meeting

By Benzinga Newsdesk

May 9, 9:21 AM

In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema and stimulated endothelial cell proliferation in the cornea Surrozen's antibody based Wnt mimetic

SRZN